IVERMECTIN | A210225 | PADAGIS ISRAEL PHARMACEUTICALS LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Argenta FDA-2026-P-6705 · 4 docket documents Argenta submitted a suitability petition on June 9, 2026, requesting FDA approval to file an Abbreviated New Animal Drug Application (ANADA) for a generic ivermectin 1.87% oral liquid for horses, which differs in dosage form from the reference listed new animal drug EQVALAN® Paste 1.87% (NADA 134-31 | Suitability | 2026-06-11 | Open | Argenta |
Withdrawal of Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2026-P-3664 · 7 docket documents Hyman, Phelps & McNamara, P.C. filed a suitability petition requesting permission under 21 C.F.R. § 314.93(b) to submit an Abbreviated New Drug Application for Ivermectin Tablets in 9 mg, 12 mg, and 15 mg strengths, which the firm withdrew on April 27, 2026. | Suitability | 2026-05-04 | Withdrawn | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$3.08
per gm
Lowest NADAC/Unit
$3.08
per gm
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 45802010284IVERMECTIN 1% CREAM | $3.08 | GM | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.